“`html
Real-world Safety and Efficacy of Sacituzumab Govitecan (SG) in Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
Key Findings:
- 132 patients with mTNBC were included in the study.
- Median progression-free survival (mPFS) was 5.2 months, and median overall survival (mOS) was 8.7 months.
- Common adverse events included fatigue, neutropenia, diarrhea, and nausea.
- 54% of patients required a reduction in SG dose.
This study demonstrates that sacituzumab govitecan (SG) shows significant anti-tumour activity in heavily pre-treated patients with metastatic triple-negative breast cancer. The findings align with the experience from clinical trials, highlighting the practical value of SG in real-world settings. The data collected from 16 tertiary UK cancer centers provides valuable insights into the safety and efficacy of SG, offering practical solutions for managing adverse events and optimizing treatment outcomes for mTNBC patients.
“`
